Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts

Jun 24 2020

• By Jessica Merrill

Listen to this article

The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021.

Money6 — A new PwC report looks at medical cost trend in 2021 • Source: Shutterstock

The anticipated launch of BioMarin Pharmaceutical Inc.'s gene therapy Roctavian (valoctocogene roxaparvovec) for hemophilia A later this year is expected to put the high cost of one-time therapies squarely on payers' radar, according to a new report from PwC's Health Research Institute (HRI) that explores medical cost trends in the US for 2021, with a focus on the impact for commercial plans and employers.

BioMarin hasn't finalized the price for Roctavian, but it's clear a drug with a $1m-plus price tag in an indication...

More from Gene Therapies

Lilly CEO Challenges ‘Small Market’ UK To Become More Attractive To Pharma - Kosh
Nov 12 2025
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances KOSH SANDBOX
Apr 24 2025
• By Kosh Naran
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Quick Listen: Scrip's Five Must-Know Things
Aug 19 2024
• By Ian Haydock
In this week's podcast edition of Five Must-Know Things: Merck & Co. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal’s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.
Gene Therapy Patient Pipeline Builds, But Slowly, In Q2
Aug 14 2024
• By Jessica Merrill
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.

More from Advanced Therapies

spo
Akash test for clone
Test article to check the clone issue
Live test
Sep 10 2024
• By Mary Jo Laffler
Progress Or Hype? A Decade Of Cell Therapy In Japan
Aug 26 2024
• By Lisa Takagi
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.